Evidence map›Paper›PMID 40217553›Full record

ArticleBiology direct2025

Lipidome atlas of p53 mutant variants in pancreatic cancer.

Kian Cotton, Charley Comer, Sabrina Caporali, Alessio Butera, Stephanie Gurres, Francesco Capradossi, Angelo D'Alessandro, Ivano Amelio, Maria Victoria Niklison-Chirou

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biology direct, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Kian CottonLife Science Department, University of Bath, Claverton Down, Bath, BA2 7AY, UK.
Charley ComerLife Science Department, University of Bath, Claverton Down, Bath, BA2 7AY, UK.
Sabrina CaporaliChair for Systems Toxicology, University of Konstanz, Constance, Germany.
Alessio ButeraChair for Systems Toxicology, University of Konstanz, Constance, Germany.
Stephanie GurresChair for Systems Toxicology, University of Konstanz, Constance, Germany.
Francesco CapradossiChair for Systems Toxicology, University of Konstanz, Constance, Germany.
Angelo D'AlessandroUniversity of Colorado Anschutz Medical Campus, Aurora, CO, 80045, USA.
Ivano AmelioChair for Systems Toxicology, University of Konstanz, Constance, Germany. ivano.amelio@uni-konstanz.de.
Maria Victoria Niklison-ChirouLife Science Department, University of Bath, Claverton Down, Bath, BA2 7AY, UK. mvnc20@bath.ac.uk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mutations in the tumour suppressor protein p53 are present in 70% of human pancreatic ductal adenocarcinomas (PDAC), subsequently to highly common activation mutation of the oncogene KRAS. These p53 mutations generate stable expression of mutant proteins, such as p53

Indexed as

Carcinoma, Pancreatic DuctalLipid MetabolismPancreatic NeoplasmsTumor Suppressor Protein p53AnimalsCell Line, TumorHumansLipidomicsMiceMutationTumor Suppressor Protein p53CancerLipidMetabolismp53 mutant

Identifiers

PMID40217553
PMCPMC11992884

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.